Combination of body mass index and @entity4493 in prognosis prediction of XXXX with squamous @entity1149 .

@entity1 @entity28 @entity5 @entity1149 @entity2 @entity4493
UNASSIGNED: @entity2 , especially @entity1149 ( @entity1149 ), represents enormous challenges in continuously achieving treatment improvements. Besides @entity5 , @entity28 is becoming ever more prevalent. Obesity is increasingly acknowledged as a major risk factor for several types of common @entity5 . Significant mechanisms overlap in the pathobiology of @entity28 and tumorigenesis. One of these mechanisms involves @entity4493 ( @entity4493 ), as a link between @entity28 and @entity5 . Additionally, body mass index (BMI) has been widely used in exploiting the role of @entity28 on a series of diseases, including @entity5 . Significantly, squamous @entity1149 revealed to be divergent clinical and molecular phenotypes compared with non-squamous @entity1149 . Consequently, @entity4493 immunostaining score and BMI were assessed by Fisher's linear discriminant analysis to discriminate if progression-free survival (PFS) would exceed 2 years. In addition, the final model was utilized to calculate the discriminant score in each study @entity1 . Finally, 131 @entity1 with squamous NCSLC were eligible for analysis. And a prediction model was established for PFS based on these 2 markers and validated in a second set of squamous NCSLC @entity1 . The model offers a novel tool for survival prediction and could establish a framework for future individualized therapy for @entity1 with squamous NCSLC.
